Financial constraints at our institution prompted us to evaluate the management of patients referred to the Acute Stroke Service because of transient ischaemic attack (TIA). We analysed age, gender, length of stay, hospital costs, discharge disposition and stroke recurrence for all cases of TIA admitted to the Acute Stroke Service between January 1, 1994, and December 31, 1996. During this time, 110 cases of TIA were admitted. All had a CT head scan, 60% had carotid Doppler ultrasound, and 30% had transthoracic echocardiography. No patients admitted with TIA died, and 92% were discharged home. The average annual cost of in-patient management of TIA was 328,000 Canadian dollars, of which 95% were accounted for by the cost of the hospital bed alone. If hospitalisation of patients with TIA could be reduced, significant cost-savings could be realised.

Keywords:
Transient ischaemic attack, Hospitalisation, Cost
1.
Warlow CP, Morris PJ: Introduction; in Warlow CP, Morris PJ (eds): Transient Ischaemic Attacks. New York, Dekker, 1982, pp vii–xi.
2.
Dennis M, Bamford J, Sandercock P, Warlow C: Prognosis of transient ischaemic attacks in the Oxfordshire Community Stroke Project. Stroke 1990;21:848–853.
3.
Warlow CP, Dennis MS, van Gijn J, Hankey GJ, Sandercock PAG, Bamford JM, Wardlaw J (eds): Stroke: A Practical Guide to Management. Oxford, Blackwell Science, 1996, pp 569–571.
4.
Antiplatelet Trialists’ Collaboration: Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81–106.
5.
North American Symptomatic Carotid Endarterectomy Trial (NASCET) Collaborators: Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325:445–453.
6.
European Carotid Surgery Trialists’ Collaborative Group: MRC European Carotid Surgery Trial: Interim results of carotid endarterectomy in symptomatic patients with severe (70–90%) or mild (0–29%) stenosis. Lancet 1991;337:1235–1243.
7.
Dean AG, Dean JA, Coulombier D, Brendel KA, Smith DC, Burton AH, Dicker RC, Sullivan K, Fagan RF, Arner TG: Epi Info Version 6: A Word Processing, Database, and Statistics Program for Epidemiology on Microcomputers. Atlanta, Centers for Disease Control and Prevention, 1994.
8.
Whisnant JP: Natural history of transient ischemic attack and ischemic stroke; in Whisnant JP (ed): Stroke: Populations, Cohorts, and Clinical Trials. Oxford, Butterworth Heineman, 1993, pp 135–153.
9.
Stroke Unit Trialist’s Collaboration: Collaborative systematic review of the randomized trials of organized inpatient (stroke unit) care after stroke. Br Med J 1997;314:1151–1159.
10.
Hankey GJ, Warlow CP: Symptomatic carotid ischaemic events: Safest and most cost effective way of selecting patients for angiography, before carotid endarterectomy. Br Med J 1990;300:1485–1491.
11.
Feinberg WM, Albers GW, Barnett HJM, Biller J, Caplan LR, Carter LP, Hart RG, Hobson RW, Kronmal RA, Moore WS, Robertson JT, Adams HP, Mayberg M: Guidelines for the Management of Transient Ischaemic Attacks. From the Ad Hoc Committee on Guidelines for Management of Transient Ischemic Attacks of the Stroke Council of the American Heart Association. Stroke 1994;25:1320–1335.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.